Dynavax Schedules Webcast to Report Q4 and YE 2007 Financial Results;
Provide 2008 Guidance
BERKELEY, Calif. (Business Wire EON/PRWEB ) February 15, 2008 --
Dynavax Technologies (Nasdaq:DVAX) will report fourth quarter and
year-end 2007 financial results and provide guidance for 2008 on
Tuesday, February 19, 2008.
A live webcast will begin at 4:15 p.m. EST (1:15 p.m. PST). The webcast
can be accessed from Dynavax’s website at www.dynavax.com
under the Investors / Events tab or by using the link http://investors.dynavax.com/events.cfm.
An archived version of the webcast will be available on the company’s
website beginning at 7:15 p.m. EST (4:15 p.m. PST) through March 4, 2008.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to
commercialize innovative TLR9 agonist-based products to treat and
prevent infectious diseases, allergies, cancer, and chronic inflammatory
diseases using versatile, proprietary approaches that alter immune
system responses in highly specific ways. Our TLR9 agonists are based on
immunostimulatory sequences, or ISS, which are short DNA sequences that
enhance the ability of the immune system to fight disease and control
chronic inflammation. Our product candidates include: HEPLISAV™,
a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBA™,
a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's
lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase
1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma
and COPD program is partnered with AstraZeneca. The National Institutes
of Health (NIH) partially funds our preclinical work on a vaccine for
influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer
trials and our hepatitis C therapeutic program, and Deerfield Management
has committed funding for our allergy programs. While Deerfield, NIH and
SDI provide program support, Dynavax has retained rights to seek
strategic partners for future development and commercialization. For
more information, please visit http://www.dynavax.com.
See the original story at: http://eon.businesswire.com/releases/dynavax/phase/prweb702304.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1JbnNlLU1hZ24tSG9yci1aZXRhLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
